Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Capital Leases (2021 - 2025)

Historic Capital Leases for Verrica Pharmaceuticals (VRCA) over the last 5 years, with Q3 2025 value amounting to $629000.0.

  • Verrica Pharmaceuticals' Capital Leases fell 6826.44% to $629000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $629000.0, marking a year-over-year decrease of 6826.44%. This contributed to the annual value of $768000.0 for FY2024, which is 2514.62% down from last year.
  • Per Verrica Pharmaceuticals' latest filing, its Capital Leases stood at $629000.0 for Q3 2025, which was down 6826.44% from $579000.0 recorded in Q2 2025.
  • Verrica Pharmaceuticals' 5-year Capital Leases high stood at $2.0 million for Q3 2024, and its period low was $13000.0 during Q2 2022.
  • Over the past 5 years, Verrica Pharmaceuticals' median Capital Leases value was $604000.0 (recorded in 2025), while the average stood at $666142.9.
  • In the last 5 years, Verrica Pharmaceuticals' Capital Leases soared by 234691.36% in 2024 and then plummeted by 6826.44% in 2025.
  • Over the past 5 years, Verrica Pharmaceuticals' Capital Leases (Quarter) stood at $16000.0 in 2021, then decreased by 18.75% to $13000.0 in 2022, then surged by 7792.31% to $1.0 million in 2023, then decreased by 25.15% to $768000.0 in 2024, then fell by 18.1% to $629000.0 in 2025.
  • Its last three reported values are $629000.0 in Q3 2025, $579000.0 for Q2 2025, and $655000.0 during Q1 2025.